Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial.
- DOI
- 10.1093/ecco-jcc/jjag049
- Published
- 2026 May 8
- Container
- Journal of Crohn's & colitis
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ecco-jcc/jjag049,
title = {Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial.},
author = {Danese S and Dignass A and Laharie D and Limdi JK and Kempinski R and Lewis JD and Younes Z and Cohen E and Alaka K and Eastman WJ and Tian T and Redondo I and Rubin DT and Dubinsky M},
year = {2026},
journal = {Journal of Crohn's \& colitis},
doi = {10.1093/ecco-jcc/jjag049},
url = {https://doi.org/10.1093/ecco-jcc/jjag049}
}RIS
TY - JOUR TI - Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial. AU - Danese S AU - Dignass A AU - Laharie D AU - Limdi JK AU - Kempinski R AU - Lewis JD AU - Younes Z AU - Cohen E AU - Alaka K AU - Eastman WJ AU - Tian T AU - Redondo I AU - Rubin DT AU - Dubinsky M PY - 2026 JO - Journal of Crohn's & colitis DO - 10.1093/ecco-jcc/jjag049 UR - https://doi.org/10.1093/ecco-jcc/jjag049 ER -
APA
S, D., A, D., D, L., JK, L., R, K., JD, L., Z, Y., E, C., K, A., WJ, E., T, T., I, R., DT, R., & M, D. (2026). Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial.. Journal of Crohn's & colitis. https://doi.org/10.1093/ecco-jcc/jjag049
Source records
- pubmed · retrieved 2026-09-26T03:27:21.157Z
- europe-pmc · retrieved 2026-09-26T03:27:21.157Z